Actylis, a global manufacturer and sourcing expert of critical materials and performance ingredients for the life science markets, has appointed Scott Thomson as CEO.
Scott has a more than 30 years experience in the pharmaceutical and chemical industries — most recently as CEO of SPI Pharma, where he helped to champion the sustainable execution of its strategic development plans.
Prior to SPI, Scott was a senior executive at BASF and was responsible for several global life science and specialty ingredients businesses.
Andre Moura, Managing Director at New Mountain Capital, commented: “Actylis has tremendous runway for sustainable growth due to its strong value proposition and market positioning. We are thrilled to invest further and support Scott and the management team to realize the company’s long-term strategic vision.”
Actylis offers standard and custom ingredients through a rapidly growing portfolio of GMP and non-GMP facilities worldwide, as well as through the company’s strong sourcing partner network.
